Safety and Effectiveness of the Single-Use Coronary Forward Intravascular Lithotripsy Catheter Combined With the Intravascular Lithotripsy Therapy Device

Inclusion Criteria: General Inclusion Criteria: * 1\) Age ≥18 years, male or female. 2)Primary coronary artery disease (with evidence of asymptomatic myocardial ischemia, stable/unstable angina, or old MI) scheduled for non-emergent PCI. 3)Pre-procedure Left Ventricular Ejection Fraction (LVEF) ≥30%. 4)Voluntarily participate in this study and sign Informed Consent Form (ICF), willing to comply with study procedures and follow-up. Angiographic Inclusion Criteria: 1. Target lesion is de novo calcified stenotic coronary lesion with no prior intervention. 2. Target lesion reference vessel diameter is 2.5-4.0 mm. 3. Target lesion meets ONE of the following: RCT part: Moderate-to-severe calcification AND stenosis ≥90% and \<100% (length ≤60 mm). (Moderate Calcification: Clearly visible high-density shadows during cardiac motion; Severe Calcification: Clearly visible high-density shadows visible without cardiac motion). Single-arm part: Calcified lesion AND Chronic Total Occlusion (CTO) (length ≤20 mm). 4. Guidewire positioned in the true lumen distal to the target lesion and not in the subintimal space prior to device use. Exclusion Criteria: General Exclusion Criteria * 1\) Planning use of scoring/cutting balloons, Excimer Laser Coronary Atherectomy (ELCA), or Coronary Intravascular Lithotripsy balloons for calcified lesion modification prior to study device use. 2\) NYHA Class III or IV. 3\) Currently on dialysis or serum creatinine level \>2.5 mg/dL (or 221 µmol/L). 4\) Severe coagulation disorder (platelet count \<100×10⁹/L). 5\) Hyperviscosity diseases (e.g., polycythemia vera, platelet count \>750×10⁹/L). 6\) Cardiac shock with clinical signs or symptoms. 7\) Active systemic infection. 8\) Moderate-to-severe anemia (hemoglobin \<90 g/L). 9\) Acute Myocardial Infarction within 1 month prior to procedure. 10\) Stroke or Transient Ischemic Attack (TIA) within 3 months prior to procedure. 11\) Active gastrointestinal ulcer or bleeding within 3 months prior to procedure. 12\) Expected life expectancy \<12 months as assessed by the investigator. 13\) Known intolerance to antiplatelet or anticoagulant therapy. 14\) Known allergy to study device components or contrast media. 15\) Known pregnancy or lactation (female subjects). 16\) Participating or planning to participate in another drug or device clinical trial. 17\) Other conditions deemed unsuitable for participation by the investigator Angiographic Exclusion Criteria: 1. Unprotected left main coronary artery disease (stenosis \>50%). 2. Serious angiographic complication in the target vessel prior to study device use. 3. Presence of thrombus or suspected thrombus in the target vessel. 4. Aneurysm within 10 mm of the target lesion in the target vessel. 5. Presence of other lesions with stenosis \>50% within the target vessel. 6. CTO lesion with excessive tortuosity (\>45°) or length \>20 mm. 7. Stent implanted within 5 mm proximal or distal to the target lesion. 8. Target lesion accessible only via saphenous vein graft (SVG) or arterial graft. 9. Failure of guidewire to successfully cross the target lesion. 10. Planned use of Antegrade Dissection Re-entry (ADR), Retrograde Wiring (RW), or Retrograde Dissection Re-entry (RDR) techniques